• These sessions provide notable exposure and recognition for studies likely to affect clinical practice significantly. Potential presenters must complete an online application outlining the purpose, design, and methods of the study. Evaluation for presentation in the Late-Breaking Clinical Trial sessions will be based on the impact and novelty of the research; rigor of the design/methods; major clinical endpoints; and the quality of the statistical plan. Priority will be given to trials whose results will be presented for the first time at ACC.07 and i2 Summit 2007.
• Investigators need not be ACC members to participate.
• There is a $100 non-refundable processing fee for each late-breaking application submitted payable online by credit card only.
• The College is unable to reimburse Annual Scientific Session and i2 Summit faculty for travel, hotel, and per diem expenses. The registration fee is waived for accepted late-breaking presenters; however, a registration form must be completed to obtain a hotel reservation and meeting badge. If you have not already registered, visit www.acc.org and click on the registration link.  If you have already registered and paid the registration fee, please request a refund in writing, attention Meeting Services ACC.07 Registrar, fax 202-375-6843.
• Notification will be sent to the person who submitted the application with final disposition information during the week of Jan. 29, 2007.
• General information subject to change due to circumstances beyond the ACC’s control.

Policies

1.   Applications must be SUBMITTED BY 11:59 p.m. CENTRAL STANDARD TIME ON THURSDAY, JANUARY 4, 2007. The American College of Cardiology is not responsible for submissions, which are not submitted by this deadline date.
2.   Submissions with system status of “incomplete” cannot be processed.
3. Submission of an application constitutes a commitment by the author(s) to present if accepted. Failure to present and register for the meeting, if not justified, will jeopardize future acceptance of applications.
4.   There is no limit to the number of applications an investigator may submit. If selected, the presenter must be one of the co-authors listed.
5.   Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected.
6.  Follow all instructions for completing the submission. Be sure to structure the content into Background, Methods, Results, and Conclusion (if known) sections.
7.   Clarity of expression will be considered in the review process. The overall quality of language used should assure comprehension by the reader.
8.   Use a maximum of five unique abbreviations in the body of the application. No abbreviations should appear in the title. Place abbreviations in parentheses after the full word the first time it appears. Abbreviations increase the difficulty of reading and evaluating applications, which will be considered in the review process.
9.   If authors' names appear on more than one application, their names must appear and be spelled identically on each application in order to facilitate proper indexing. Whenever possible, do not list authors with initials only.
10.   Any abstract presenting data that in whole or part is contained in a Late-Breaking Clinical Trial submission that was submitted in September for presentation in the general program cannot be presented in the regular program and must be withdrawn if that trial is accepted for presentation as a Late-Breaking Trial. Please notify Dianne Lee djlee@acc.org or Kristin Turner kturner@acc.org if another abstract based on the clinical trial was submitted via the regular abstract submission process.
11.   After the deadline, the system will be closed, and submissions will be forwarded for the reviewing process. An author may not revise or resubmit an application in order to make changes or corrections after the deadline. Proofread applications carefully to avoid errors before they are submitted. ACC is not authorized to make changes to a submission. If you choose to withdraw an application after the submission deadline, this request must be received by ACC in writing. Please notify Dianne Lee djlee@acc.org.
12.   Applications are not eligible for consideration if the data have been presented at a U.S. or international meeting held before the 56th Annual Scientific Session.
13.   Applications are not eligible for consideration if the data have been published before the 56th Annual Scientific Session.
14.   Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association.
15.   The ACC.07 and i2 Summit Program Committees endorse the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.
16.   Each presenting author will be asked to comply with the ACCF “Statement of Disclosure (Vested Interest) and Conflict of Interest for Accredited Educational Activities” Policy. Indication of the relationship, the associated commercial entity and level of support is required for each author at the time of submission. Again this year, all presenters at ACC.07 and i2 Summit 2007 must display a slide at the beginning of their presentation indicating disclosure information as applicable, or that they have nothing to disclose.
17.   The submitter acts on behalf of all co-authors and in submitting an application, transfers to the American College of Cardiology the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following: a) all proprietary rights other than copyright, such as patent rights; and b) the right to use all or part of the application in future works of their own. The American College of Cardiology, as holder of the copyright on the accepted application, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.
18.   In light of increased attention to the manner in which research results (particularly those affecting the stock of publicly-traded companies) are made public, ACC is clarifying its policies and procedures regarding disclosure of applications. All applications submitted are disclosed to members of the peer review selection committee, as well as to ACC employees and contractors as necessary in connection with the annual meeting. Those applications that are accepted for presentation are summarized for publication after the Annual Scientific Session and are not publicly available to the public in advance of the annual meeting. The usual procedures for summarizing presentations are set forth below under “Accepted Submissions.” Applications not accepted for presentation are not summarized, and are ordinarily not disclosed outside of ACC and persons associated with the selection process (i.e., the peer review committee). Notwithstanding these policies and procedures, ACC is not subject to any confidentiality requirements with respect to submitted applications. In addition, compliance with any disclosure or nondisclosure requirements that apply to researchers or research sponsors (whether under federal securities laws, contract agreement, or otherwise) is the sole responsibility of the researcher and/or sponsor, and not the ACC.
19.  All authors must comply with the ACC embargo policy, which states that scientific study results to be presented during the Annual Scientific Session and i2 Summit must nor be revealed to the public prior to the scheduled time of presentation at ACC.07 or i2 Summit 2007 or the ACC-sponsored press conference, whichever one comes first.  This includes presentations at satellite meetings or press conferences held before the scheduled Annual Scientific Session scientific presentation.  This also means that if media representatives contact abstract authors/presenters and/or company sponsors, any information must be given with the understanding that material is under embargo until the time of presentation or ACC-sponsored press conference. Abstract authors/presenters and/or company sponsors who ignore the embargo rules run the risk of being withdrawn from the program.  Furthermore, if there are public health concerns regarding the embargoed material, the authors/presenters and/or company sponsors must seek ACC approval before revealing any embargoed content.
20. Investigator meetings: The only exception to the above mentioned embargo rules are closed investigator meetings for participants in the trial. These meetings must be held at the Annual Scientific Session and may be held beginning Friday, March 23, 2007. The Annual Scientific Session and i2 Summit Program Committees wish to be apprized of these meetings. If your trial submission is accepted for presentation, you will be asked to supply investigator meeting date/time/location information with your acceptance material.